‘‘(q) SPECIFIC PURPOSES.—
‘‘(1) IN GENERAL.—The Director shall ensure 
that, of the amounts appropriated for a fiscal year 
for the Program, at least $7,000,000 is used in high 
intensity drug trafficking areas with severe neigh-
borhood safety and illegal drug distribution prob-
lems. 
‘‘(2) REQUIRED USES.—The funds used under 
paragraph (1) shall be used—
‘‘(A) to ensure the safety of neighborhoods 
and the protection of communities, including 
the prevention of the intimidation of potential 
witnesses of illegal drug distribution and related 
activities; and 
‘‘(B) to combat illegal drug trafficking 
through such methods as the Director considers 
appropriate, such as establishing or operating 
(or both) a toll-free telephone hotline for use by 
the public to provide information about illegal 
drug-related activities.’’. 
SEC. 11. AMENDMENTS RELATING TO COUNTER-DRUG 
TECHNOLOGY ASSESSMENT CENTER. 
(a) CHIEF SCIENTIST.—Section 708(b) (21 U.S.C. 
1707(b)) is amended—
(1) in the heading by striking ‘‘DIRECTOR OF 
TECHNOLOGY.—’’ 
and 
inserting 
‘‘CHIEF
SCI-
ENTIST.—’’; and 
(2) by striking ‘‘Director of Technology,’’ and 
inserting ‘‘Chief Scientist,’’. 
(b) ADDITIONAL RESPONSIBILITIES OF DIRECTOR.—
Section 708(c) (21 U.S.C. 1707(c)) is amended to read 
as follows: 
‘‘(c) ADDITIONAL RESPONSIBILITIES OF THE DIREC-
TOR OF NATIONAL DRUG CONTROL POLICY.—
‘‘(1) 
IN
GENERAL.—The 
Director, 
acting 
through the Chief Scientist shall—
‘‘(A) identify and define the short-, me-
dium-, and long-term scientific and techno-
logical needs of Federal, State, and local law 
enforcement agencies relating to drug enforce-
ment, including—
‘‘(i) advanced surveillance, tracking, 
and radar imaging; 
‘‘(ii) electronic support measures; 
‘‘(iii) communications; 
‘‘(iv) data fusion, advanced computer 
systems, and artificial intelligence; and
‘‘(v) chemical, biological, radiological 
(including neutron, electron, and graviton), 
and other means of detection; 
‘‘(B) identify demand reduction (including 
drug prevention) basic and applied research 
needs and initiatives, in consultation with af-
fected National Drug Control Program agen-
cies, including—
‘‘(i) improving treatment through 
neuroscientific advances; 
‘‘(ii) improving the transfer of bio-
medical research to the clinical setting; and 
‘‘(iii) in consultation with the Na-
tional Institute on Drug Abuse and the 
Substance Abuse and Mental Health Serv-
ices Administration, and through inter-
agency agreements or grants, examining 
addiction and rehabilitation research and 
the application of technology to expanding 
the effectiveness or availability of drug 
treatment; 
‘‘(C) make a priority ranking of such needs 
identified in subparagraphs (A) and (B) accord-
ing to fiscal and technological feasibility, as
part of a National Counterdrug Research and 
Development Program; 
‘‘(D) oversee and coordinate counterdrug 
technology initiatives with related activities of 
other Federal civilian and military departments; 
‘‘(E) provide support to the development 
and implementation of the national drug control 
performance measurement system established 
under subsection (b) of section 706; 
‘‘(F) with the advice and counsel of experts 
from State and local law enforcement agencies, 
oversee and coordinate a technology transfer 
program for the transfer of technology to State 
and local law enforcement agencies; and 
‘‘(G) pursuant to the authority of the Di-
rector of National Drug Control Policy under 
section 704, submit requests to Congress for 
the reprogramming or transfer of funds appro-
priated for counterdrug technology research and 
development. 
‘‘(2) PRIORITIES
IN
TRANSFERRING
TECH-
NOLOGY.—
‘‘(A) IN
GENERAL.—The Chief Scientist 
shall give priority, in transferring technology
under paragraph (1)(F), based on the following 
criteria: 
‘‘(i) the need of potential recipients 
for such technology; 
‘‘(ii) the effectiveness of the tech-
nology to enhance current counterdrug ac-
tivities of potential recipients; and 
‘‘(iii) the ability and willingness of po-
tential recipients to evaluate transferred 
technology. 
‘‘(B) INTERDICTION
AND
BORDER
DRUG 
LAW
ENFORCEMENT
TECHNOLOGIES.—The 
Chief Scientist shall give priority, in transfer-
ring technologies most likely to assist in drug 
interdiction and border drug law enforcement, 
to State, local, and tribal law enforcement agen-
cies in southwest border areas and northern 
border areas with significant traffic in illicit 
drugs. 
‘‘(3) LIMITATION ON AUTHORITY.—The author-
ity granted to the Director under this subsection 
shall not extend to the direct management of indi-
vidual projects or other operational activities. 
‘‘(4) REPORT.—On or before July 1 of each 
year, the Director shall submit a report to the ap-
propriate congressional committees that addresses 
the following: 
‘‘(A) The number of requests received dur-
ing the previous 12 months, including the iden-
tity of each requesting agency and the type of 
technology requested. 
‘‘(B) The number of requests fulfilled dur-
ing the previous 12 months, including the iden-
tity of each recipient agency and the type of 
technology transferred. 
‘‘(C) A summary of the criteria used in 
making the determination on what requests 
were funded and what requests were not fund-
ed, except that such summary shall not include 
specific information on any individual requests. 
‘‘(D) A general assessment of the future 
needs of the program, based on expected 
changes in threats, expected technologies, and 
likely need from potential recipients. 
‘‘(E) An assessment of the effectiveness of 
the technologies transferred, based in part on 
the evaluations provided by the recipients, with 
a recommendation whether the technology 
should continue to be offered through the pro-
gram.’’.
(c) ASSISTANCE FROM SECRETARY OF HOMELAND 
SECURITY.—Section 708(d) (21 U.S.C. 1707(d)) is 
amended by inserting ‘‘, the Secretary of Homeland Secu-
rity,’’ after ‘‘The Secretary of Defense’’. 
SEC. 12. NATIONAL YOUTH ANTIDRUG MEDIA CAMPAIGN. 
(a) IN GENERAL.—Section 709 (21 U.S.C. 1708) is 
amended to read as follows: 
‘‘SEC. 709. NATIONAL YOUTH ANTIDRUG MEDIA CAMPAIGN. 
‘‘(a) IN GENERAL.—The Director shall conduct a na-
tional youth anti-drug media campaign (referred to in this 
subtitle as the ‘national media campaign’) in accordance 
with this section for the purposes of—
‘‘(1) preventing drug abuse among young peo-
ple in the United States; 
‘‘(2) increasing awareness of adults of the im-
pact of drug abuse on young people; and 
‘‘(3) encouraging parents and other interested 
adults to discuss with young people the dangers of 
illegal drug use. 
‘‘(b) USE OF FUNDS.—
‘‘(1) IN GENERAL.—Amounts made available to 
carry out this section for the national media cam-
paign may only be used for the following:
‘‘(A) The purchase of media time and 
space, including the strategic planning for, and 
accounting of, such purchases. 
‘‘(B) Creative and talent costs, consistent 
with paragraph (2)(A). 
‘‘(C) Advertising production costs. 
‘‘(D) Testing and evaluation of advertising. 
‘‘(E) Evaluation of the effectiveness of the 
national media campaign. 
‘‘(F) The negotiated fees for the winning 
bidder on requests for proposals issued either 
by the Office or its designee to enter into con-
tracts to carry out activities authorized by this 
section. 
‘‘(G) Partnerships with professional and 
civic groups, community-based organizations, 
including faith-based organizations, and govern-
ment organizations related to the national 
media campaign. 
‘‘(H) Entertainment industry outreach, 
interactive outreach, media projects and activi-
ties, public information, news media outreach, 
and corporate sponsorship and participation. 
‘‘(I) Operational and management ex-
penses.
‘‘(2) SPECIFIC REQUIREMENTS.—
‘‘(A) CREATIVE SERVICES.—
‘‘(i) In using amounts for creative and 
talent costs under paragraph (1)(B), the 
Director shall use creative services donated 
at no cost to the Government (including 
creative services provided by the Partner-
ship for a Drug-Free America) wherever 
feasible and may only procure creative 
services for advertising—
‘‘(I) responding to high-priority 
or emergent campaign needs that can-
not timely be obtained at no cost; or 
‘‘(II) intended to reach a minor-
ity, ethnic, or other special audience 
that cannot reasonably be obtained at 
no cost; or 
‘‘(III) the Director determines 
that the Partnership for a Drug-Free 
America is unable to provide, pursu-
ant to subsection (d)(2)(B). 
‘‘(ii) Subject to the availability of ap-
propriations, no more than $1,500,000 
may be expended under this section each 
fiscal year on creative services, except that
the Director may expend up to $2,000,000 
in a fiscal year on creative services to meet 
urgent needs of the national media cam-
paign with advance approval from the 
Committee on Appropriations of the House 
of Representatives and of the Senate upon 
a showing of the circumstances causing 
such urgent needs of the national media 
campaign. 
‘‘(B) TESTING AND EVALUATION OF AD-
VERTISING.—In using amounts for testing and 
evaluation of advertising under paragraph 
(1)(D), the Director shall test all advertise-
ments prior to use in the national media cam-
paign to ensure that the advertisements are ef-
fective and meet industry-accepted standards. 
The Director may waive this requirement for 
advertisements using no more than 10 percent 
of the purchase of advertising time purchased 
under this section in a fiscal year and no more 
than 10 percent of the advertising space pur-
chased under this section in a fiscal year, if the 
advertisements respond to emergent and time-
sensitive campaign needs or the advertisements
will not be widely utilized in the national media 
campaign. 
‘‘(C) EVALUATION OF EFFECTIVENESS OF 
MEDIA CAMPAIGN.—In using amounts for the 
evaluation of the effectiveness of the national 
media campaign under paragraph (1)(E), the 
Director shall—
‘‘(i) designate an independent entity 
to evaluate annually the effectiveness of 
the national media campaign based on 
data from—
‘‘(I) the Monitoring the Future 
Study published by the Department of 
Health and Human Services; 
‘‘(II) 
the 
Attitude 
Tracking 
Study published by the Partnership 
for a Drug Free America; 
‘‘(III) the National Household 
Survey on Drug Abuse; and 
‘‘(IV) other relevant studies or 
publications, as determined by the Di-
rector, including tracking and evalua-
tion data collected according to mar-
keting and advertising industry stand-
ards; and
‘‘(ii) ensure that the effectiveness of 
the national media campaign is evaluated 
in a manner that enables consideration of 
whether the national media campaign has 
contributed to reduction of illicit drug use 
among youth and such other measures of 
evaluation as the Director determines are 
appropriate. 
‘‘(3) PURCHASE
OF
ADVERTISING
TIME
AND 
SPACE.—Subject to the availability of appropria-
tions, for each fiscal year, not less than 77 percent 
of the amounts appropriated under this section shall 
be used for the purchase of advertising time and 
space for the national media campaign, subject to 
the following exceptions: 
‘‘(A) In any fiscal year for which less than 
$125,000,000 is appropriated for the national 
media campaign, not less than 82 percent of 
the amounts appropriated under this section 
shall be used for the purchase of advertising 
time and space for the national media cam-
paign. 
‘‘(B) In any fiscal year for which more 
than $195,000,000 is appropriated under this 
section, not less than 72 percent shall be used
for advertising production costs and the pur-
chase of advertising time and space for the na-
tional media campaign. 
‘‘(c) ADVERTISING.—In carrying out this section, the 
Director shall ensure that sufficient funds are allocated 
to meet the stated goals of the national media campaign. 
‘‘(d) DIVISION
OF RESPONSIBILITIES
AND FUNC-
TIONS UNDER THE PROGRAM.—
‘‘(1) IN GENERAL.—The Director, in consulta-
tion with the Partnership for a Drug-Free America, 
shall determine the overall purposes and strategy of 
the national media campaign. 
‘‘(2) RESPONSIBILITIES.—
‘‘(A) DIRECTOR.—The Director shall be 
responsible for implementing a focused national 
media campaign to meet the purposes set forth 
in subsection (a), and shall approve—
‘‘(i) the strategy of the national media 
campaign; 
‘‘(ii) all advertising and promotional 
material used in the national media cam-
paign; and 
‘‘(iii) the plan for the purchase of ad-
vertising time and space for the national 
media campaign.
‘‘(B) THE
PARTNERSHIP
FOR
A
DRUG-
FREE
AMERICA.—The Director shall request 
that the Partnership for a Drug-Free Amer-
ica—
‘‘(i) develop and recommend strategies 
to achieve the goals of the national media 
campaign, including addressing national 
and local drug threats in specific regions 
or States, such as methamphetamine and 
ecstasy; 
‘‘(ii) create all advertising to be used 
in the national media campaign, except ad-
vertisements that are—
‘‘(I) provided by other nonprofit 
entities pursuant to subsection (f); 
‘‘(II) intended to respond to 
high-priority or emergent campaign 
needs that cannot timely be obtained 
at no cost (not including production 
costs and talent reuse payments), pro-
vided that any such advertising mate-
rial is reviewed by the Partnership for 
a Drug-Free America; 
‘‘(III) intended to reach a minor-
ity, ethnic, or other special audience
that cannot be obtained at no cost 
(not including production costs and 
talent reuse payments), provided that 
any such advertising material is re-
viewed by the Partnership for a Drug-
Free America; or 
‘‘(IV) any other advertisements 
that the Director determines that the 
Partnership for a Drug-Free America 
is unable to provide. 
‘‘(C) MEDIA
BUYING
CONTRACTOR.—The 
Director shall enter into a contract with a 
media buying contractor to plan and purchase 
advertising time and space for the national 
media campaign. The media buying contractor 
shall not provide any other service or material, 
or conduct any other function or activity which 
the Director determines should be provided by 
the Partnership for a Drug-Free America. 
‘‘(e) PROHIBITIONS.—None of the amounts made 
available under subsection (b) may be obligated or ex-
pended for any of the following: 
‘‘(1) To supplant current antidrug community-
based coalitions.
‘‘(2) To supplant pro bono public service time 
donated by national and local broadcasting networks 
for other public service campaigns. 
‘‘(3) For partisan political purposes, or express 
advocacy in support of or to defeat any clearly iden-
tified candidate, clearly identified ballot initiative, or 
clearly identified legislative or regulatory proposal. 
‘‘(4) To fund advertising that features any 
elected officials, persons seeking elected office, cabi-
net level officials, or other Federal officials employed 
pursuant to section 213 of Schedule C of title 5, 
Code of Federal Regulations. 
‘‘(5) To fund advertising that does not contain 
a primary message intended to reduce or prevent il-
licit drug use. 
‘‘(6) To fund advertising containing a primary 
message intended to promote support for the media 
campaign or private sector contributions to the 
media campaign. 
‘‘(f) MATCHING REQUIREMENT.—
‘‘(1) IN
GENERAL.—Amounts made available 
under subsection (b) for media time and space shall 
be matched by an equal amount of non-Federal 
funds for the national media campaign, or be
matched with in-kind contributions of the same 
value. 
‘‘(2) NO-COST MATCH ADVERTISING DIRECT RE-
LATIONSHIP REQUIREMENT.—The Director shall en-
sure that at least 70 percent of no-cost match adver-
tising provided directly relates to substance abuse 
prevention consistent with the specific purposes of 
the national media campaign, except that in any fis-
cal year in which less than $125,000,000 is appro-
priated to the national media campaign, the Director 
shall ensure that at least 85 percent of no-cost 
match advertising directly relates to substance abuse 
prevention consistent with the specific purposes of 
the national media campaign. 
‘‘(3) NO-COST
MATCH
ADVERTISING
NOT
DI-
RECTLY RELATED.—The Director shall ensure that 
no-cost match advertising that does not directly re-
late to substance abuse prevention consistent with 
the purposes of the national media campaign in-
cludes a clear antidrug message. Such message is 
not required to be the primary message of the match 
advertising. 
‘‘(g) FINANCIAL
AND
PERFORMANCE
ACCOUNT-
ABILITY.—The Director shall cause to be performed—
‘‘(1) audits and reviews of costs of the national 
media campaign pursuant to section 304C of the 
Federal Property and Administrative Services Act of 
1949 (41 U.S.C. 254d); and 
‘‘(2) an audit to determine whether the costs of 
the national media campaign are allowable under 
section 306 of such Act (41 U.S.C. 256). 
‘‘(h) REPORT
TO CONGRESS.—The Director shall 
submit on an annual basis a report to Congress that de-
scribes—
‘‘(1) the strategy of the national media cam-
paign and whether specific objectives of the media 
campaign were accomplished; 
‘‘(2) steps taken to ensure that the national 
media campaign operates in an effective and effi-
cient manner consistent with the overall strategy 
and focus of the national media campaign; 
‘‘(3) plans to purchase advertising time and 
space; 
‘‘(4) policies and practices implemented to en-
sure that Federal funds are used responsibly to pur-
chase advertising time and space and eliminate the 
potential for waste, fraud, and abuse; and
‘‘(5) all contracts entered into with a corpora-
tion, partnership, or individual working on behalf of 
the national media campaign. 
‘‘(i) LOCAL TARGET REQUIREMENT.—The Director 
shall, to the maximum extent feasible, use amounts made 
available under this section for media that focuses on, or 
includes specific information on, prevention or treatment 
resources for consumers within specific local areas. 
‘‘(j) PREVENTION OF MARIJUANA USE.—
‘‘(1) FINDINGS.—The Congress finds the fol-
lowing: 
‘‘(A) 60 percent of adolescent admissions 
for drug treatment are based on marijuana use. 
‘‘(B) Potency levels of contemporary mari-
juana, particularly hydroponically grown mari-
juana, are significantly higher than in the past, 
rising from under 1 percent of THC in the mid-
1970s to as high as 30 percent today. 
‘‘(C) Contemporary research has dem-
onstrated that youths smoking marijuana early 
in life may be up to five times more likely to 
use hard drugs. 
‘‘(D) Contemporary research has dem-
onstrated clear detrimental effects in adolescent
educational achievement resulting from mari-
juana use. 
‘‘(E) Contemporary research has dem-
onstrated clear detrimental effects in adolescent 
brain development resulting from marijuana 
use. 
‘‘(F) An estimated 9,000,000 Americans a 
year drive while under the influence of illegal 
drugs, including marijuana. 
‘‘(G) Marijuana smoke contains 50 to 70 
percent more of certain cancer causing chemi-
cals than tobacco smoke. 
‘‘(H) Teens who use marijuana are up to 
four times more likely to have a teen pregnancy 
than teens who have not. 
‘‘(I) Federal law enforcement agencies 
have identified clear links suggesting that trade 
in hydroponic marijuana facilitates trade by 
criminal organizations in hard drugs, including 
heroin. 
‘‘(J) Federal law enforcement agencies 
have identified possible links between trade in 
cannabis products and financing for terrorist 
organizations.
‘‘(2) EMPHASIS
ON
PREVENTION
OF
YOUTH 
MARIJUANA USE.—In conducting advertising and ac-
tivities otherwise authorized under this section, the 
Director may emphasize prevention of youth mari-
juana use. 
‘‘(k) PREVENTION OF METHAMPHETAMINE ABUSE 
AND OTHER EMERGING DRUG ABUSE THREATS.—
‘‘(1) REQUIREMENT TO USE 10 PERCENT OF 
FUNDS
FOR
METHAMPHETAMINE
ABUSE
PREVEN-
TION.—The Director shall ensure that, of the 
amounts appropriated under this section for the na-
tional media campaign for a fiscal year, not less 
than 10 percent shall be expended solely for—
‘‘(A) the activities described subsection 
(b)(1) with respect to advertisements specifi-
cally intended to reduce the use of methamphet-
amine; and 
‘‘(B) grants under paragraph (2). 
‘‘(2) GRANT
AUTHORITY.—The Director may 
award grants to private entities for purposes of 
methamphetamine 
media 
projects. 
Any 
such 
project—
‘‘(A) shall have as its goal the significant 
reduction of the prevalence of first-time meth-
amphetamine use among young people; and
‘‘(B) shall focus solely on the prevention of 
methamphetamine use, through, at a minimum, 
public service messages that are based on re-
search showing what is effective in substantially 
reducing such use among young people, includ-
ing public service messages in both print and 
electronic media and on websites. 
‘‘(3) AUTHORITY TO USE FUNDS FOR OTHER 
DRUG
ABUSE
UPON
CERTIFICATION
THAT
METH-
AMPHETAMINE ABUSE FELL DURING FISCAL YEAR 
2007.—With respect to fiscal year 2008 and any fis-
cal year thereafter, if the Director certifies in writ-
ing to Congress that domestic methamphetamine 
laboratory seizures (as reported to the El Paso Intel-
ligence Center of the Drug Enforcement Administra-
tion) decreased by at least 75 percent from the 2006 
level, the Director may apply paragraph (1)(A) for 
that fiscal year with respect to advertisements spe-
cifically intended to reduce the use of such other 
drugs as the Director considers appropriate. 
‘‘(l) AUTHORIZATION OF APPROPRIATIONS.—There is 
authorized to be appropriated to the Office to carry out 
this section, $195,000,000 for each of fiscal years 2007 
and 2008 and $210,000,000 for each of fiscal years 2009 
through 2011.’’.
(b) REPEAL
OF SUPERSEDED PROVISIONS.—The 
Drug-Free Media Campaign Act of 1998 (21 U.S.C. 1801 
et seq.) is repealed. 
SEC. 13. DRUG INTERDICTION. 
(a) IN GENERAL.—Subsections (a) and (b) of section 
711 (21 U.S.C. 1710) are amended to read as follows: 
‘‘(a) UNITED
STATES
INTERDICTION
COORDI-
NATOR.—
‘‘(1) IN GENERAL.—The Deputy Director for 
Supply Reduction in the Office shall serve as the 
United States Interdiction Coordinator, and shall 
perform the duties of that position described in 
paragraph (2) and such other duties as may be de-
termined by the Director with respect to coordina-
tion of efforts to interdict illicit drugs from entering 
the United States. 
‘‘(2) RESPONSIBILITIES.—The United States 
Interdiction Coordinator shall be responsible to the 
Director for—
‘‘(A) coordinating the interdiction activities 
of the National Drug Control Program agencies 
to ensure consistency with the National Drug 
Control Strategy; 
‘‘(B) on behalf of the Director, developing 
and issuing, on or before March 1 of each year
and in accordance with paragraph (3), a Na-
tional Interdiction Command and Control Plan 
to ensure the coordination and consistency de-
scribed in subparagraph (A); 
‘‘(C) assessing the sufficiency of assets 
committed to illicit drug interdiction by the rel-
evant National Drug Control Program agencies; 
and 
‘‘(D) advising the Director on the efforts 
of each National Drug Control Program agency 
to implement the National Interdiction Com-
mand and Control Plan. 
‘‘(3) STAFF.—The Director shall assign such 
permanent staff of the Office as he considers appro-
priate to assist the United States Interdiction Coor-
dinator to carry out the responsibilities described in 
paragraph (2), and may also, at his discretion, re-
quest that appropriate National Drug Control Pro-
gram agencies detail or assign staff to the Office of 
Supply Reduction for that purpose. 
‘‘(4) NATIONAL INTERDICTION COMMAND AND 
CONTROL PLAN.—
‘‘(A) PURPOSES.—The National Interdic-
tion Command and Control Plan shall—
‘‘(i) set forth the Government’s strat-
egy for drug interdiction; 
‘‘(ii) state the specific roles and re-
sponsibilities of the relevant National Drug 
Control Program agencies for imple-
menting that strategy; and 
‘‘(iii) identify the specific resources re-
quired to enable the relevant National 
Drug Control Program agencies to imple-
ment that strategy. 
‘‘(B) CONSULTATION WITH OTHER AGEN-
CIES.—The United States Interdiction Coordi-
nator shall issue the National Interdiction Com-
mand and Control Plan in consultation with the 
other members of the Interdiction Committee 
described in subsection (b). 
‘‘(C) LIMITATION.—The National Interdic-
tion Command and Control Plan shall not 
change existing agency authorities or the laws 
governing interagency relationships, but may in-
clude recommendations about changes to such 
authorities or laws. 
‘‘(D) REPORT TO CONGRESS.—On or be-
fore March 1 of each year, the United States 
Interdiction Coordinator shall provide a report
on behalf of the Director to the appropriate 
congressional committees, to the Committee on 
Armed Services and the Committee on Home-
land Security of the House of Representatives, 
and to the Committee on Homeland Security 
and Governmental Affairs and the Committee 
on Armed Services of the Senate, which shall 
include—
‘‘(i) a copy of that year’s National 
Interdiction Command and Control Plan; 
‘‘(ii) information for the previous 10 
years regarding the number and type of 
seizures of drugs by each National Drug 
Control Program agency conducting drug 
interdiction activities, as well as statistical 
information on the geographic areas of 
such seizures; and 
‘‘(iii) information for the previous 10 
years regarding the number of air and 
maritime patrol hours undertaken by each 
National Drug Control Program agency 
conducting drug interdiction activities, as 
well as statistical information on the geo-
graphic areas in which such patrol hours 
took place.
‘‘(E) TREATMENT OF CLASSIFIED OR LAW 
ENFORCEMENT SENSITIVE INFORMATION.—Any 
content of the report described in subparagraph 
(D) that involves information classified under 
criteria established by an Executive order, or 
the public disclosure of which, as determined by 
the Director, the Director of National Intel-
ligence, or the head of any Federal Government 
agency the activities of which are described in 
the plan, would be detrimental to the law en-
forcement or national security activities of any 
Federal, State, or local agency, shall be pre-
sented to Congress separately from the rest of 
the report. 
‘‘(b) INTERDICTION COMMITTEE.—
‘‘(1) IN
GENERAL.—The Interdiction Com-
mittee shall meet to—
‘‘(A) discuss and resolve issues related to 
the coordination, oversight and integration of 
international, border, and domestic drug inter-
diction efforts in support of the National Drug 
Control Strategy; 
‘‘(B) review the annual National Interdic-
tion Command and Control Plan, and provide 
advice to the Director and the United States
Interdiction Coordinator concerning that plan; 
and 
‘‘(C) provide such other advice to the Di-
rector concerning drug interdiction strategy and 
policies as the committee determines is appro-
priate. 
‘‘(2) MEMBERSHIP.—The membership of the 
Interdiction Committee shall consist of—
‘‘(A) the Commissioner of the bureau of 
Customs and Border Protection at the Depart-
ment of Homeland Security; 
‘‘(B) the Assistant Secretary of the bureau 
of Immigration and Customs Enforcement at 
the Department of Homeland Security; 
‘‘(C) the Commandant of the United 
States Coast Guard; 
‘‘(D) the Director of the Office of Counter-
narcotics Enforcement at the Department of 
Homeland Security; 
‘‘(E) the Administrator of the Drug En-
forcement Administration; 
‘‘(F) the Assistant Secretary of State for 
International Narcotics and Law Enforcement 
Affairs;
100
‘‘(G) the Assistant Secretary of Defense 
for Special Operations and Low Intensity Con-
flict; 
‘‘(H) the Deputy Director for Supply Re-
duction of the Office of National Drug Control 
Policy, acting in his role as the United States 
Interdiction Coordinator; 
‘‘(I) the director of the Crime and Nar-
cotics Center of the Central Intelligence Agen-
cy; 
‘‘(J) the Deputy Director for State and 
Local Affairs of the Office of National Drug 
Control Policy; 
‘‘(K) the Chief of the National Guard Bu-
reau’s Counterdrug Program; and 
‘‘(L) such additional persons as may be de-
termined by the Director. 
‘‘(3) CHAIRMAN.—The Director shall designate 
one of the members of the Interdiction Committee to 
serve as chairman. 
‘‘(4) MEETINGS.—The members of the Interdic-
tion Committee shall meet, in person and not 
through any delegate or representative, at least once 
per calendar year, prior to March 1. At the call of 
either the Director or the current chairman, the
101
Interdiction Committee may hold additional meet-
ings, which shall be attended by the members either 
in person, or through such delegates or representa-
tives as they may choose. 
‘‘(5) REPORT.—Not later than September 30 of 
each year, the chairman of the Interdiction Com-
mittee shall submit a report to the Director and to 
the appropriate congressional committees describing 
the results of the meetings and any significant find-
ings of the Committee during the previous 12 
months. Any content of such a report that involves 
information classified under criteria established by 
an Executive order, or whose public disclosure, as 
determined by the Director, the chairman, or any 
member, would be detrimental to the law enforce-
ment or national security activities of any Federal, 
State, or local agency, shall be presented to Con-
gress separately from the rest of the report.’’. 
(b) CONFORMING AMENDMENT TO HOMELAND SE-
CURITY ACT OF 2002.—Section 878 of the Homeland Se-
curity Act of 2002 (6 U.S.C. 458) is amended—
(1) in subsection (c), by striking ‘‘Except as 
provided in subsection (d), the’’ and inserting 
‘‘The’’; and
102
(2) by striking subsection (d) and redesignating 
subsections (e), (f), and (g) as subsections (d), (e), 
and (f), respectively. 
SEC. 14. AWARDS FOR DEMONSTRATION PROGRAMS BY 
LOCAL PARTNERSHIPS TO SHUT DOWN IL-
LICIT DRUG MARKET HOT-SPOTS BY DETER-
RING DRUG DEALERS OR ALTERING THE DY-
NAMIC OF DRUG SALES. 
Sections 713 and 714 (21 U.S.C. 1711) are redesig-
nated as sections 715 and 716, respectively, and after sec-
tion 712 (21 U.S.C. 1710) insert the following new sec-
tion: 
‘‘SEC. 713 AWARDS FOR DEMONSTRATION PROGRAMS BY 
LOCAL PARTNERSHIPS TO SHUT DOWN IL-
LICIT DRUG MARKET HOT-SPOTS BY DETER-
RING DRUG DEALERS OR ALTERING THE DY-
NAMIC OF DRUG SALES. 
‘‘(a) AWARDS REQUIRED.—The Director shall make 
competitive awards for demonstration programs by eligible 
partnerships for the purpose of shutting down local illicit 
drug market hot-spots and reducing drug-related crime 
through evidence-based, strategic problem-solving inter-
ventions that deter drug dealers or alter the dynamic of 
drug sales.
103
‘‘(b) USE OF AWARD AMOUNTS.—Award amounts re-
ceived under this section shall be used—
‘‘(1) to support the efforts of the agencies, or-
ganizations, and researchers included in the eligible 
partnership; 
‘‘(2) to develop and field a directed and credible 
deterrent threat; and 
‘‘(3) to strengthen rehabilitation efforts through 
such means as job training, drug treatment, or other 
services. 
‘‘(c) ELIGIBLE PARTNERSHIP DEFINED.—In this 
section, the term ‘eligible partnership’ means a working 
group whose application to the Director—
‘‘(1) identifies the roles played, and certifies the 
involvement of, three or more agencies or organiza-
tions, which may include—
‘‘(A) State or local agencies (such as those 
carrying out police, probation, prosecution, 
courts, corrections, parole, or treatment func-
tions); 
‘‘(B) Federal agencies (such as the Drug 
Enforcement Agency, the Bureau of Alcohol, 
Tobacco, Firearms, and Explosives, and United 
States Attorney offices); and 
‘‘(C) community-based organizations;
104
‘‘(2) includes a qualified researcher; 
‘‘(3) includes a plan for identifying the impact 
players in, and assessing the nature and dynamic of, 
the local drug market and its related crime through 
information gathering and analysis; 
‘‘(4) includes a plan for developing an evidence-
based strategic intervention aimed at quickly and 
sustainably eradicating the local drug market by de-
terring drug dealers or altering the dynamic of drug 
sales; and 
‘‘(5) includes a plan that describes the method-
ology and outcome measures proposed for evaluating 
the impact of that strategic intervention on drug 
sales, neighborhood disorder, and crime. 
‘‘(d) REPORTS TO CONGRESS.—
‘‘(1) INTERIM REPORT.—Not later than June 1, 
2009, the Director shall submit to Congress a report 
that identifies the best practices in drug market 
eradication, including the best practices identified 
through the activities funded under this section. 
‘‘(2) FINAL REPORT.—Not later than June 1, 
2010, the Director shall submit to Congress a report 
on the demonstration programs funded under this 
section, including on the matters specified in para-
graph (1).
105
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to carry out this section 
$10,000,000 for each of fiscal years 2007 through 2009.’’. 
SEC. 15. AWARDS FOR DEMONSTRATION PROGRAMS BY 
LOCAL PARTNERSHIPS TO COERCE ABSTI-
NENCE 
IN 
CHRONIC 
HARD-DRUG 
USERS 
UNDER COMMUNITY SUPERVISION THROUGH 
THE USE OF DRUG TESTING AND SANCTIONS. 
After section 713, as inserted by section 14 of this 
Act, insert the following new section: 
‘‘SEC. 714. AWARDS FOR DEMONSTRATION PROGRAMS BY 
LOCAL PARTNERSHIPS TO COERCE ABSTI-
NENCE 
IN 
CHRONIC 
HARD-DRUG 
USERS 
UNDER COMMUNITY SUPERVISION THROUGH 
THE USE OF DRUG TESTING AND SANCTIONS. 
‘‘(a) AWARDS REQUIRED.—The Director shall make 
competitive awards to fund demonstration programs by el-
igible partnerships for the purpose of reducing the use of 
illicit drugs by chronic hard-drug users living in the com-
munity while under the supervision of the criminal justice 
system. 
‘‘(b) USE OF AWARD AMOUNTS.—Award amounts re-
ceived under this section shall be used—
106
‘‘(1) to support the efforts of the agencies, or-
ganizations, and researchers included in the eligible 
partnership; 
‘‘(2) to develop and field a drug testing and 
graduated sanctions program for chronic hard-drug 
users living in the community under criminal justice 
supervision; and 
‘‘(3) to assist individuals described in sub-
section (a) by strengthening rehabilitation efforts 
through such means as job training, drug treatment, 
or other services. 
‘‘(c) ELIGIBLE PARTNERSHIP DEFINED.—In this 
section, the term ‘eligible partnership’ means a working 
group whose application to the Director—
‘‘(1) identifies the roles played, and certifies the 
involvement of, two or more agencies or organiza-
tions, which may include—
‘‘(A) State or local agencies (such as those 
carrying out police, probation, prosecution, 
courts, corrections, parole, or treatment func-
tions); 
‘‘(B) Federal agencies (such as the Drug 
Enforcement Agency, the Bureau of Alcohol, 
Tobacco, Firearms, and Explosives, and United 
States Attorney offices); and
107
‘‘(C) community-based organizations; 
‘‘(2) includes a qualified researcher; 
‘‘(3) includes a plan for using judicial or other 
criminal justice authority to administer drug tests to 
individuals described in subsection (a) at least twice 
a week, and to swiftly and certainly impose a known 
set of graduated sanctions for non-compliance with 
community-release provisions relating to drug absti-
nence (whether imposed as a pre-trial, probation, or 
parole condition or otherwise); 
‘‘(4) includes a strategy for responding to a 
range of substance use and abuse problems and a 
range of criminal histories; 
‘‘(5) includes a plan for integrating data infra-
structure among the agencies and organizations in-
cluded in the eligible partnership to enable seamless, 
real-time tracking of individuals described in sub-
section (a); 
‘‘(6) includes a plan to monitor and measure 
the progress toward reducing the percentage of the 
population of individuals described in subsection (a) 
who, upon being summoned for a drug test, either 
fail to show up or who test positive for drugs. 
‘‘(d) REPORTS TO CONGRESS.—
108
‘‘(1) INTERIM REPORT.—Not later than June 1, 
2009, the Director shall submit to Congress a report 
that identifies the best practices in reducing the use 
of illicit drugs by chronic hard-drug users, including 
the best practices identified through the activities 
funded under this section. 
‘‘(2) FINAL REPORT.—Not later than June 1, 
2010, the Director shall submit to Congress a report 
on the demonstration programs funded under this 
section, including on the matters specified in para-
graph (1). 
‘‘(e) AUTHORIZATION OF APPROPRIATIONS.—There 
is authorized to be appropriated to carry out this section 
$10,000,000 for each of fiscal years 2007 through 2009.’’. 
SEC. 16. AUTHORIZATION OF APPROPRIATIONS. 
Section 716 (21 U.S.C. 1711), as redesignated by 
section 14 of this Act, is amended—
(1) by striking ‘‘title,’’ and inserting ‘‘title, ex-
cept activities for which amounts are otherwise spe-
cifically authorized by this title,’’; and 
(2) by striking ‘‘1999 through 2003’’ and in-
serting ‘‘2007 through 2011’’. 
SEC. 17. TECHNICAL AMENDMENTS AND REPEAL. 
(a) AMENDMENT TO PUBLIC HEALTH SERVICE ACT 
TO REPLACE OBSOLETE REFERENCES.—Section 464P(c)
109
of the Public Health Service Act (42 U.S.C. 285o–4(c)) 
is amended—
(1) in paragraph (1), by striking ‘‘under section 
1002 of the Anti-Drug Abuse Act of 1988 (21 
U.S.C. 1501)’’ and inserting ‘‘under section 703 of 
the Office of National Drug Control Policy Reau-
thorization Act of 1998 (21 U.S.C. 1702)’’; and 
(2) in paragraph (2), by striking ‘‘under section 
1005 of the Anti-Drug Abuse Act of 1988 (21 
U.S.C. 1504)’’ and inserting ‘‘under section 706 of 
the Office of National Drug Control Policy Reau-
thorization Act of 1998 (21 U.S.C. 1705)’’. 
(b) REPEAL OF SPECIAL FORFEITURE FUND.—Sec-
tion 6073 of the Asset Forfeiture Amendments Act of 
1988 (21 U.S.C. 1509) is repealed. 
SEC. 18. REQUIREMENT FOR DISCLOSURE OF FEDERAL 
SPONSORSHIP 
OF 
ALL 
FEDERAL 
ADVER-
TISING OR OTHER COMMUNICATION MATE-
RIALS. 
Section 712 is amended to read as follows:
110
‘‘SEC. 712. REQUIREMENT FOR DISCLOSURE OF FEDERAL 
SPONSORSHIP 
OF 
ALL 
FEDERAL 
ADVER-
TISING OR OTHER COMMUNICATION MATE-
RIALS. 
‘‘(a) REQUIREMENT.—Each advertisement or other 
communication paid for by the Office, either directly or 
through a contract awarded by the Office, shall include 
a prominent notice informing the target audience that the 
advertisement or other communication is paid for by the 
Office. 
‘‘(b) ADVERTISEMENT
OR
OTHER
COMMUNICA-
TION.—In this section, the term ‘advertisement or other 
communication’ includes—
‘‘(1) an advertisement disseminated in any 
form, including print or by any electronic means; 
and 
‘‘(2) a communication by an individual in any 
form, including speech, print, or by any electronic 
means.’’. 
SEC. 19. POLICY RELATING TO SYRINGE EXCHANGE PRO-
GRAMS. 
Section 703(a) (21 U.S.C. 1702(a)) is amended by 
adding at the end the following: 
‘‘When developing the national drug control policy, any 
policy of the Director relating to syringe exchange pro-
grams for intravenous drug users shall be based on the
111
best available medical and scientific evidence regarding 
their effectiveness in promoting individual health and pre-
venting the spread of infectious disease, and their impact 
on drug addiction and use. In making any policy relating 
to syringe exchange programs, the Director shall consult 
with the National Institutes of Health and the National 
Academy of Sciences.’’. 
SEC. 20. INTERNATIONAL SUMMIT ON METHAMPHETAMINE 
THREAT. 
(a) SUMMIT REQUIREMENT.—The Director of the 
Office of National Drug Control Policy in the Executive 
Office of the President shall, in consultation with the Sec-
retary of State, the Attorney General, the Secretary of 
Homeland Security, the Secretary of Health and Human 
Services, and the United States Trade Representative, 
seek to convene an international summit on the threat of 
methamphetamine and synthetic drug precursor chemi-
cals. 
(b) PARTICIPATION
OF OTHER COUNTRIES.—The 
Director shall seek to convene the summit with the partici-
pation and involvement of government leaders at the high-
est level from all countries that are direct sources of pre-
cursor chemicals and from all countries that are affected 
by methamphetamine production, trafficking, and use, to 
intensify and coordinate an effective international re-
112
sponse in order to prevent methamphetamine production 
and precursor diversion. 
(c) INTERNATIONAL AGREEMENTS.—The Director 
shall encourage the negotiation, drafting, and ratification 
of multilateral or bilateral agreements that may contain 
information-sharing treaties concerning provisions for pre-
cursor importation and exportation and additional provi-
sions for annual assessments of medical and scientific 
needs of each signatory country. 
(d) MATTERS ADDRESSED BY THE SUMMIT.—The 
summit may address the following: 
(1) The greater involvement of international po-
licing and customs organizations, such as Interpol, 
the United Nations Office on Drugs and Crime, and 
the World Customs Organization. 
(2) Expanding resources and hired persons to 
track 
international 
shipments 
of 
ephedrine, 
pseudoephedrine, and other precursor substances as 
controlled by the International Narcotics Control 
Board. 
(3) Working with the private sector and Fed-
eral agencies, as well as the World Health Organiza-
tion, to support the research and development of 
substances that can effectively replace primary pre-
cursors used in the manufacture of synthetic drugs.
113
(e) DEADLINE.—The Director shall seek to convene 
the summit not later than 12 months after the date of 
the enactment of this Act and follow-up summits in subse-
quent years as the Director finds necessary. 
(f) AUTHORIZATION
OF APPROPRIATIONS.—There 
are authorized to be appropriated to the Director 
$1,000,000 to carry out this section. 
SEC. 21. STUDY ON DRUG COURT HEARINGS IN NONTRADI-
TIONAL PLACES. 
(a) FINDING.—Congress finds that encouraging drug 
courts and schools to enter into partnerships that allow 
students to see the repercussions of drug abuse by non-
violent offenders may serve as a strong deterrent and pro-
mote demand reduction. 
(b) STUDY.—The Director of the Office of National 
Drug Control Policy shall conduct a study on drug court 
programs that conduct hearings in nontraditional public 
places, such as schools. At a minimum, the study shall 
evaluate similar programs in operation, such as the pro-
gram operated in the Fourth Judicial District Drug 
Court, in Washington County, Arkansas. 
(c) REQUIREMENT.—At the same time the President 
submits to Congress the National Drug Control Strategy 
due February 1, 2007, pursuant to section 706 of the Of-
fice of National Drug Control Policy Reauthorization Act
114
of 1998, the President shall submit to Congress a report 
on the study conducted under subsection (b). The report 
shall include an evaluation of the results of the study and 
such recommendations as the President considers appro-
priate. 
(d) DEMAND REDUCTION.—In this section, the term 
‘‘demand reduction’’ has the meaning provided in section 
702(1) of the Office of National Drug Control Policy Re-
authorization Act of 1998 (21 U.S.C. 1701(1)). 
SEC. 22. REPORT ON GOVERNMENT-SPONSORED METH-
AMPHETAMINE CONFERENCE. 
(a) REPORT.—Not later than 30 days after the date 
of the enactment of this Act, the Director of the Office 
of National Drug Control Policy shall submit to Congress 
a report explaining the rationale and circumstances lead-
ing to the sponsorship by the Department of Health and 
Human Resources, and the participation by employees of 
such department, in a conference conducted by the Harm 
Reduction Coalition and the Harm Reduction Project on 
August 19th and 20th, 2005, in Salt Lake City, Utah, 
titled the ‘‘1st National Conference on Methamphetamine, 
HIV, and Hepatitis Science & Response’’. 
(b) ADDITIONAL MATTERS COVERED.—The report 
shall include a description of the management and report-
ing systems of the Office of National Drug Control Policy